Skip to main content


Fig. 5 | BMC Biotechnology

Fig. 5

From: The production of a recombinant tandem single chain fragment variable capable of binding prolamins triggering celiac disease

Fig. 5

Comparison of the binding capability of refolded tscFv and tscFv inclusion bodies (IBs). A, PT-gliadin ELISA where 10, 2 and 0.4 μg/mL refolded tscFv and 100, 10 or 1 μg/mL lyophilized and resuspended IBs were used; B, competitive ELISA, IBs (400 μg/mL) or refolded tscFv (40 μg/mL) were applied with PT-gliadin and sample buffer. Signal reductions show that the samples are binding to increasing concentrations of PT-gliadin in the supernatant and not to the immobilized PT-gliadin on the plates

Back to article page